Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Declines By 49.2%

Plus Therapeutics, Inc. (NASDAQ:PSTVGet Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 48,900 shares, a drop of 49.2% from the April 15th total of 96,300 shares. Based on an average trading volume of 207,300 shares, the days-to-cover ratio is currently 0.2 days.

PSTV has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Plus Therapeutics in a report on Friday, April 22nd. Zacks Investment Research cut Plus Therapeutics from a “buy” rating to a “sell” rating in a report on Thursday, April 28th.

Plus Therapeutics stock opened at $0.46 on Friday. Plus Therapeutics has a 1 year low of $0.41 and a 1 year high of $2.95. The business has a 50-day moving average of $0.88 and a 200-day moving average of $1.11. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.49 and a current ratio of 4.49.

Plus Therapeutics (NASDAQ:PSTVGet Rating) last posted its earnings results on Thursday, February 24th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts anticipate that Plus Therapeutics will post -0.76 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Plus Therapeutics by 97.6% during the 3rd quarter. Geode Capital Management LLC now owns 258,437 shares of the company’s stock worth $493,000 after buying an additional 127,644 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Plus Therapeutics during the 4th quarter worth about $217,000. Otter Creek Advisors LLC acquired a new position in shares of Plus Therapeutics during the 1st quarter worth about $84,000. Citadel Advisors LLC acquired a new position in shares of Plus Therapeutics during the 4th quarter worth about $87,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics during the 4th quarter worth about $35,000. Institutional investors own 8.69% of the company’s stock.

Plus Therapeutics Company Profile (Get Rating)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Read More

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.